LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: Evaluating the Impact of Omega-3 Free Fatty Acid Supplementation on Postoperative Complications in Obese Postmenopausal Women With Estrogen Receptor Positive Breast Cancer.

Kahlenberg, Zachary B / Rodriguez, Marisa F / Brenner, Andrew / Kaklamani, Virginia G

2020 Volume 89, Issue 4, Page(s) 1144–1146

MeSH term(s)	Female ; Humans ; Breast Neoplasms/surgery ; Breast Neoplasms/complications ; Fatty Acids, Omega-3/therapeutic use ; Fatty Acids, Nonesterified ; Receptors, Estrogen ; Postmenopause ; Obesity/complications ; Dietary Supplements ; Postoperative Complications/prevention & control
Chemical Substances	Fatty Acids, Omega-3 ; Fatty Acids, Nonesterified ; Receptors, Estrogen
Language	English
Publishing date	2020-12-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	202465-2
ISSN	1555-9823 ; 0003-1348
ISSN (online)	1555-9823
ISSN	0003-1348
DOI	10.1177/0003134820979790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Engineering Carboxylic Acid Reductase (CAR) through a Whole-Cell Growth-Coupled NADPH Recycling Strategy.

Kramer, Levi / Le, Xuan / Rodriguez, Marisa / Wilson, Mark A / Guo, Jiantao / Niu, Wei

ACS synthetic biology

2020 Volume 9, Issue 7, Page(s) 1632–1637

Abstract: Rapid evolution of enzyme activities is often hindered by the lack of efficient and affordable methods to identify beneficial mutants. We report the development of a new growth-coupled selection method for evolving NADPH-consuming enzymes based on the ... ...

Abstract	Rapid evolution of enzyme activities is often hindered by the lack of efficient and affordable methods to identify beneficial mutants. We report the development of a new growth-coupled selection method for evolving NADPH-consuming enzymes based on the recycling of this redox cofactor. The method relies on a genetically modified
MeSH term(s)	Adipates/chemistry ; Adipates/metabolism ; Catalytic Domain ; Glycols/chemistry ; Glycols/metabolism ; Hydroxybenzoate Ethers/chemistry ; Hydroxybenzoate Ethers/metabolism ; Kinetics ; Mutagenesis, Site-Directed ; NADP/metabolism ; Oxidation-Reduction ; Oxidoreductases/chemistry ; Oxidoreductases/genetics ; Oxidoreductases/metabolism ; Protein Engineering/methods ; Salicylates/chemistry ; Salicylates/metabolism
Chemical Substances	Adipates ; Glycols ; Hydroxybenzoate Ethers ; Salicylates ; 2-methoxybenzoic acid (49WA6Z7GZA) ; NADP (53-59-8) ; adipic acid (76A0JE0FKJ) ; Oxidoreductases (EC 1.-) ; carboxylic acid reductase (EC 1.3.99.-) ; hexamethylene glycol (ZIA319275I)
Language	English
Publishing date	2020-07-06
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2161-5063
ISSN (online)	2161-5063
DOI	10.1021/acssynbio.0c00290
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Group prenatal care and improved birth outcomes: Results from a type 1 hybrid effectiveness-implementation study.

Lewis, Jessica B / Cunningham, Shayna D / Shabanova, Veronika / Hassan, Sonia S / Magriples, Urania / Rodriguez, Marisa G / Ickovics, Jeannette R

Preventive medicine

2021 Volume 153, Page(s) 106853

Abstract: To compare birth outcomes for patients receiving Expect With Me (EWM) group prenatal care or individual care only, we conducted a type 1 hybrid effectiveness-implementation trial (Detroit and Nashville, 2014-2016). Participants entered care <24 weeks ... ...

Abstract	To compare birth outcomes for patients receiving Expect With Me (EWM) group prenatal care or individual care only, we conducted a type 1 hybrid effectiveness-implementation trial (Detroit and Nashville, 2014-2016). Participants entered care <24 weeks gestation, had singleton pregnancy, and no prior preterm birth (N = 2402). Mean participant age was 27.1 (SD = 5.77); 49.5% were Black; 15.3% were Latina; 59.7% publicly insured. Average treatment effect of EWM compared to individual care only was estimated using augmented inverse probability weighting (AIPW). This doubly-robust analytic method produces estimates of causal association between treatment and outcome in the absence of randomization. AIPW was effective at creating equivalent groups for potential confounders. Compared to those receiving individual care only, EWM patients did significantly better on three of four primary outcomes: lower risk of infants born preterm (<37 weeks gestation; 6.4% vs. 15.1%, risk ratio (RR) 0.42, 95% Confidence Interval (CI) 0.29, 0.54), low birthweight (<2500 g; 4.3% vs. 11.6%, RR 0.37, 95% CI 0.24, 0.49), and admission to NICU (9.4% vs. 14.6%, RR 0.64, 95% CI 0.49, 0.78). There was no difference in small for gestational age (<10% percentile of weight for gestational age). EWM patients attended a mean of 5.9 group visits (SD = 2.7); 70% attended ≥5 group visits. Post-hoc analyses indicated EWM patients utilizing the integrated information technology platform had lower risk for low birthweight infants (RR 0.47, 95% CI 0.24, 0.86) than non-users. Future research is needed to understand mechanisms by which group prenatal care improves outcomes, best practices for implementation, and health systems savings. Trial registration: ClinicalTrials.govNCT02169024.
MeSH term(s)	Adult ; Female ; Gestational Age ; Humans ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Small for Gestational Age ; Pregnancy ; Premature Birth ; Prenatal Care/methods
Language	English
Publishing date	2021-10-20
Publishing country	United States
Document type	Clinical Trial ; Journal Article
ZDB-ID	184600-0
ISSN	1096-0260 ; 0091-7435
ISSN (online)	1096-0260
ISSN	0091-7435
DOI	10.1016/j.ypmed.2021.106853
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 878: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Image analysis of lutrol/gelucire/olanzapine microspheres prepared by ultrasound-assisted spray congealing.

Cavallari, Cristina / Gonzalez-Rodriguez, Marisa / Tarterini, Fabrizio / Fini, Adamo

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

2014 Volume 88, Issue 3, Page(s) 909–918

Abstract: Nine systems were prepared containing Gelucire 50/13 and various amounts (9-18-36-45% w/w) of Lutrol F68 and F127 in the presence and in the absence of 10% w/w of olanzapine and formulated as a solid dispersion in the form of microspheres by ultrasound ( ... ...

Abstract	Nine systems were prepared containing Gelucire 50/13 and various amounts (9-18-36-45% w/w) of Lutrol F68 and F127 in the presence and in the absence of 10% w/w of olanzapine and formulated as a solid dispersion in the form of microspheres by ultrasound (US)-assisted spray congealing. Thermal analysis, using differential scanning calorimetry (DSC) and thermomicroscopy (HSM), suggested the presence of particles of reduced size of olanzapine precipitated inside the microspheres. The microspheres were also studied by means of electron microscopy (SEM) for their shape and aspect, by some image analysis parameters (fractal dimension) and using Energy-dispersive X-ray (X-EDS) and micro-Raman spectroscopy to qualitatively evaluate the composition of different points of the surface. The surface of the microspheres displayed a non-homogeneous distribution of the drug by the presence of wart-like protuberances, whose number increases as the Lutrol content of the systems increases. The same systems in the absence of US, obtained after cooling the molten mixtures, lack these structures and only a very few of them can be found. The blooming of the surface was hypothesized as related to crystallization or phase de-mixing or lipid component diffusion of the carrier mixture inside the cooling mass subjected to ultrasound vibration. Ultrasounds accelerate the physical changes concerning carriers and drug, outlining the importance of ultrasound to achieve stability for formulations of this type. The microspheres de-aggregate on contact with the dissolution medium and release the drug with a bimodal mode according to the Lutrol content.
MeSH term(s)	Benzodiazepines/analysis ; Benzodiazepines/chemistry ; Calorimetry, Differential Scanning/methods ; Chemistry, Pharmaceutical/methods ; Fats/analysis ; Fats/chemistry ; High-Energy Shock Waves ; Microspheres ; Oils/analysis ; Oils/chemistry ; Polyethylene Glycols/analysis ; Polyethylene Glycols/chemistry ; Spectrum Analysis, Raman/methods
Chemical Substances	Fats ; Lutrol ; Oils ; Gelucire 50-13 (121548-05-8) ; Benzodiazepines (12794-10-4) ; Polyethylene Glycols (30IQX730WE) ; olanzapine (N7U69T4SZR)
Language	English
Publishing date	2014-11
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1065368-5
ISSN	1873-3441 ; 0939-6411
ISSN (online)	1873-3441
ISSN	0939-6411
DOI	10.1016/j.ejpb.2014.08.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1651: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry.

López-Oliva, María O / Pérez-Flores, Isabel / Molina, María / José Aladrén, María / Trujillo, Hernando / Redondo-Pachón, Dolores / López, Verónica / Facundo, Carme / Villanego, Florentino / Rodríguez, Marisa / Carmen Ruiz, Maria / Antón, Paula / Rivas-Oural, Alba / Cabello, Sheila / Portolés, José / de la Vara, Lourdes / Tabernero, Guadalupe / Valero, Rosalía / Galeano, Cristina /

Moral, Esperanza / Ventura, Ana / Coca, Armando / Ángel Muñoz, Miguel / Hernández-Gallego, Román / Shabaka, Amir / Ledesma, Gabriel / Bouarich, Hanane / Ángeles Rodríguez, María / Pérez Tamajón, Lourdes / Cruzado, Leónidas / Emilio Sánchez, José / Jiménez, Carlos

Nefrologia

2023 Volume 43, Issue 4, Page(s) 442–451

Abstract: Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the ... ...

Abstract	Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated. Objectives: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis. Material and methods: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis. Results: renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7 ± 0.8, 2.1 ± 1.2 and 1.8 ± 1 mg/dl respectively (p < 0.001). 56.9% of the patients (N = 350) were monitored for anti-HLA antibodies. 94% (N = 329) had no anti-HLA changes, while 6% (N = 21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N = 9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant. Conclusions: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis.
MeSH term(s)	Humans ; Male ; Middle Aged ; Female ; Tacrolimus/therapeutic use ; Retrospective Studies ; Mycophenolic Acid/therapeutic use ; Kidney Transplantation ; Prednisone ; Nephrology ; COVID-19 Testing ; RNA, Viral ; COVID-19 ; SARS-CoV-2 ; Immunosuppressive Agents/therapeutic use ; Immunosuppression Therapy ; Antilymphocyte Serum
Chemical Substances	Tacrolimus (WM0HAQ4WNM) ; Mycophenolic Acid (HU9DX48N0T) ; Prednisone (VB0R961HZT) ; RNA, Viral ; Immunosuppressive Agents ; Antilymphocyte Serum
Language	English
Publishing date	2023-09-01
Publishing country	Spain
Document type	Multicenter Study ; Journal Article
ZDB-ID	2837917-2
ISSN	2013-2514 ; 2013-2514
ISSN (online)	2013-2514
ISSN	2013-2514
DOI	10.1016/j.nefroe.2023.08.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Characterization of Streptococcus pneumoniae invasive serotype 19A isolates from Argentina (1993-2014).

Gagetti, Paula / Faccone, Diego / Reijtman, Vanesa / Fossati, Sofia / Rodriguez, Marisa / Veliz, Omar / Ceriana, Paola / Regueira, Mabel / Corso, Alejandra

Vaccine

2017 Volume 35, Issue 35 Pt B, Page(s) 4548–4553

Abstract: The aim of this study was to characterize Streptococcus pneumoniae serotype 19A isolates causing invasive pneumococcal disease in children, collected in Argentina between 1993 and 2014. A total of 176 isolates serotype 19A were analyzed. There was an ... ...

Abstract	The aim of this study was to characterize Streptococcus pneumoniae serotype 19A isolates causing invasive pneumococcal disease in children, collected in Argentina between 1993 and 2014. A total of 176 isolates serotype 19A were analyzed. There was an increase in the proportion of serotype 19A isolates from 3% in 1993 to 6% in 2011, prior to the introduction of PCV13 in 2012, and from 2012 to 2014 its proportion gradually decreased. Penicillin resistance among serotype 19A isolates throughout the study period was 65.9%, but a significant increase was observed from 0% in 1993 to 87.5% in 2014. Genetic relationship of the isolates was determined by PFGE and selected strains were studied by MLST. Most of the isolates belonged to two clonal types: A (54.5%) and B (11.4%). Isolates of clonal type A were ST1131, a single locus variant of ST172 and accounted for 54% of the total collection. They were detected for the first time in our country in 1997 and most of them (93%) were penicillin non susceptible. Isolates of clonal type B were ST8121, a single locus variant of ST199, and were mainly susceptible to penicillin. These two clonal types are still in circulation and appear to be responsible for the dissemination of S. pneumoniae serotype 19A invasive isolates in our country.
Language	English
Publishing date	2017-08-16
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2017.07.030
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾

Article ; Online: Diclofenac salts, part 6: release from lipid microspheres.

Fini, Adamo / Cavallari, Cristina / Rabasco Alvarez, Antonio M / Rodriguez, Marisa Gonzalez

Journal of pharmaceutical sciences

2011 Volume 100, Issue 8, Page(s) 3482–3494

Abstract: The release of diclofenac (20%, w/w) was studied from lipidic solid dispersions using three different chemical forms (acid, sodium salt, and pyrrolidine ethanol salt) and two different lipid carriers (Compritol 888 ATO or Carnauba wax) either free or ... ...

Abstract	The release of diclofenac (20%, w/w) was studied from lipidic solid dispersions using three different chemical forms (acid, sodium salt, and pyrrolidine ethanol salt) and two different lipid carriers (Compritol 888 ATO or Carnauba wax) either free or together with varying amounts (10%-30%, w/w) of stearic acid. Microspheres were prepared by ultrasound-assisted atomization of the molten dispersions and analyzed by scanning electron microscopy, differential scanning calorimetry, and hot stage microscopy. The effects of different formulations on the resulting drug release profiles as a function of pH were studied and the results were discussed. The formulation of the 18 systems and the chemical form of the drug were found to strongly affect the mode of the drug release. The solubility of the chemical forms in the lipid mixture is in the following order: pyrrolidine ethanol salt ≫ acid > sodium salt (according to the solubility parameters), and the nature of the systems thus obtained ranges from a matrix, for mutually soluble drug/carrier pairs, to a microcapsule, for pairs wherein mutual solubility is poor. Drug release from microspheres prepared by pure lipids was primarily controlled by diffusion, whereas the release from microspheres containing stearic acid was diffusion/erosion controlled at pH 7.4.
MeSH term(s)	Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/chemistry ; Calorimetry, Differential Scanning ; Diclofenac/administration & dosage ; Diclofenac/chemistry ; Drug Carriers/chemistry ; Drug Compounding ; Fatty Acids/chemistry ; Glycerol/analogs & derivatives ; Hot Temperature ; Lipids/chemistry ; Microscopy ; Microscopy, Electron, Scanning ; Microspheres ; Polyethylene Glycols ; Salts ; Solubility ; Stearic Acids/chemistry ; Surface Properties ; Thermography ; Waxes/chemistry
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Drug Carriers ; Fatty Acids ; Lipids ; Salts ; Stearic Acids ; Waxes ; compritol HD5 ATO ; Diclofenac (144O8QL0L1) ; glyceryl behenate (18641-57-1) ; Polyethylene Glycols (30IQX730WE) ; stearic acid (4ELV7Z65AP) ; Glycerol (PDC6A3C0OX) ; carnauba wax (R12CBM0EIZ)
Language	English
Publishing date	2011-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3151-3
ISSN	1520-6017 ; 0022-3549
ISSN (online)	1520-6017
ISSN	0022-3549
DOI	10.1002/jps.22581
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.50: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Manejo de la inmunosupresión en pacientes trasplantados de riñón con COVID19. Estudio multicéntrico nacional derivado del registro COVID de la S.E.N.

López-Oliva, María O / Pérez-Flores, Isabel / Molina, María / José Aladrén, Mª / Trujillo, Hernando / Redondo-Pachón, Dolores / López, Verónica / Facundo, Carme / Villanego, Florentino / Rodríguez, Marisa / Carmen Ruiz, Mª / Antón, Paula / Rivas-Oural, Alba / Cabello, Sheila / Portolés, José / de la Vara, Lourdes / Tabernero, Guadalupe / Valero, Rosalía / Galeano, Cristina /

Moral, Esperanza / Ventura, Ana / Coca, Armando / Muñoz, Miguel Ángel / Hernández-Gallego, Román / Shabaka, Amir / Ledesma, Gabriel / Martínez, Patricia / Ángeles Rodríguez, Mª / Tamajón, Lourdes Pérez / Cruzado, Leónidas / Emilio Sánchez, J / Jiménez, Carlos

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

2022

Title translation	Management of immunosuppressive therapy in kidney transplant recipients with COVID19. A multicentre national study derived form the S.E.N. COVID registry.
Abstract	Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated. Objectives: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis. Material and methods: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis. Results: 615 renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years.The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased.Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7±0.8, 2.1±1.2 and 1.8±1 mg/dl respectively (p<0.001).56.9% of the patients (N=350) were monitored for anti-HLA antibodies. 94% (N=329) had no anti-HLA changes, while 6% (N=21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N=9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant. Conclusions: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis.
Language	Spanish
Publishing date	2022-04-30
Publishing country	Spain
Document type	English Abstract ; Journal Article
ZDB-ID	632512-9
ISSN	1989-2284 ; 0211-6995
ISSN (online)	1989-2284
ISSN	0211-6995
DOI	10.1016/j.nefro.2022.03.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2773: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 56: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Directed -in vitro- evolution of Precambrian and extant Rubiscos.

Gomez-Fernandez, Bernardo J / Garcia-Ruiz, Eva / Martin-Diaz, Javier / Gomez de Santos, Patricia / Santos-Moriano, Paloma / Plou, Francisco J / Ballesteros, Antonio / Garcia, Monica / Rodriguez, Marisa / Risso, Valeria A / Sanchez-Ruiz, Jose M / Whitney, Spencer M / Alcalde, Miguel

Scientific reports

2018 Volume 8, Issue 1, Page(s) 5532

Abstract: Rubisco is an ancient, catalytically conserved yet slow enzyme, which plays a central role in the biosphere's carbon cycle. The design of Rubiscos to increase agricultural productivity has hitherto relied on the use of in vivo selection systems, ... ...

Abstract	Rubisco is an ancient, catalytically conserved yet slow enzyme, which plays a central role in the biosphere's carbon cycle. The design of Rubiscos to increase agricultural productivity has hitherto relied on the use of in vivo selection systems, precluding the exploration of biochemical traits that are not wired to cell survival. We present a directed -in vitro- evolution platform that extracts the enzyme from its biological context to provide a new avenue for Rubisco engineering. Precambrian and extant form II Rubiscos were subjected to an ensemble of directed evolution strategies aimed at improving thermostability. The most recent ancestor of proteobacteria -dating back 2.4 billion years- was uniquely tolerant to mutagenic loading. Adaptive evolution, focused evolution and genetic drift revealed a panel of thermostable mutants, some deviating from the characteristic trade-offs in CO
MeSH term(s)	Amino Acid Sequence ; Carbon Dioxide/metabolism ; Directed Molecular Evolution ; Kinetics ; Models, Molecular ; Phylogeny ; Protein Conformation ; Rhodospirillum/enzymology ; Ribulose-Bisphosphate Carboxylase/metabolism ; Sequence Homology
Chemical Substances	Carbon Dioxide (142M471B3J) ; Ribulose-Bisphosphate Carboxylase (EC 4.1.1.39)
Language	English
Publishing date	2018-04-03
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-018-23869-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin.

Pollock, Brad H / Elmore, Sarah / Romoser, Amelia / Tang, Lili / Kang, Min-Su / Xue, Kathy / Rodriguez, Marisa / Dierschke, Nicole A / Hayes, Holly G / Hansen, H Andrew / Guerra, Fernando / Wang, Jia-Sheng / Phillips, Timothy

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment

2016 Volume 33, Issue 8, Page(s) 1346–1354

Abstract: South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be ...

Abstract	South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be present in a variety of foods in the United States, including corn and corn products. Importantly, it is a dietary risk factor contributing to a higher incidence of HCC in populations frequently consuming AFB1-contaminated diets. In a randomised double-blind placebo controlled trial, we evaluated the effects of a 3-month administration of ACCS100 (refined calcium montmorillonite clay) on serum AFB1-lysine adduct (AFB-Lys) level and serum biochemistry in 234 healthy men and women residing in Bexar and Medina counties, Texas. Participants recruited from 2012 to 2014 received either a placebo, 1.5 g or 3 g ACCS100 each day for 3 months, and no treatment during the fourth month. Adverse event rates were similar across treatment groups and no significant differences were observed for serum biochemistry and haematology parameters. Differences in levels of AFB-Lys at 1, 3 and 4 months were compared between placebo and active treatment groups. Although serum AFB-Lys levels were decreased by month 3 for both treatment groups, the low dose was the only treatment that was significant (p = 0.0005). In conclusion, the observed effect in the low-dose treatment group suggests that the use of ACCS100 may be a viable strategy to reduce dietary AFB1 bioavailability during aflatoxin outbreaks and potentially in populations chronically exposed to this carcinogen.
MeSH term(s)	Adult ; Aflatoxin B1/administration & dosage ; Aflatoxin B1/blood ; Aluminum Silicates/administration & dosage ; Aluminum Silicates/therapeutic use ; Bentonite/administration & dosage ; Bentonite/adverse effects ; Bentonite/therapeutic use ; Biomarkers ; Calcium/administration & dosage ; Calcium/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Poisons/administration & dosage ; Poisons/blood ; Texas
Chemical Substances	ACCS100 ; Aluminum Silicates ; Biomarkers ; Poisons ; Bentonite (1302-78-9) ; clay (1302-87-0) ; Aflatoxin B1 (9N2N2Y55MH) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2016-08
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2462951-0
ISSN	1944-0057 ; 1944-0049
ISSN (online)	1944-0057
ISSN	1944-0049
DOI	10.1080/19440049.2016.1198498
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito